Ftse Mib
33.968,78
1,01%
DAX
18.175,21
1,01%
S&P 500
5.161,78
0,66%
NASDAQ
16.271,82
0,71%
Bitcoin
63.265,77
-1,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xenon Pharmaceuticals Inc (XENE) Xenon Pharmaceuticals Inc (XENE) Notizie

Xenon Pharmaceuticals Inc

XENE
43,54
-0,21 (-0,48%)
Ultimo aggiornamento: 18:43:52
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
16/4/202414:30GLOBEXenon Pharmaceuticals Showcases XEN1101 at the American..
04/4/202422:01GLOBEXenon Pharmaceuticals to Present at the 23rd Annual Needham..
12/3/202421:01GLOBEXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS..
09/3/202400:47EDGAR2Form 144 - Report of proposed sale of securities
08/3/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:27EDGAR2Form 8-K - Current report
08/3/202401:04EDGAR2Form 144 - Report of proposed sale of securities
08/3/202401:03EDGAR2Form 144 - Report of proposed sale of securities
05/3/202422:01GLOBEXenon Pharmaceuticals to Present at Leerink Partners Global..
29/2/202422:10EDGAR2Form 8-K - Current report
29/2/202422:01GLOBEXenon Pharmaceuticals Reports Fourth Quarter and Full Year..
22/2/202422:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
14/2/202415:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202414:00GLOBEXenon Pharmaceuticals Outlines Key Milestone Opportunities..
03/1/202414:30GLOBEXenon Pharmaceuticals to Present at the 42nd Annual J.P...
02/1/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202322:16GLOBEXenon Pharmaceuticals Announces Closing of $345.0 Million..
02/12/202318:01GLOBEXenon Pharmaceuticals Provides Updates on Neurology Pipeline..
30/11/202322:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/11/202322:15EDGAR2Form 8-K - Current report
30/11/202304:51GLOBEXenon Pharmaceuticals Announces Pricing of Upsized $300.0..
29/11/202323:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202322:03GLOBEXenon Pharmaceuticals Announces Proposed Public Offering
27/11/202313:03EDGAR2Form 8-K - Current report
27/11/202313:00GLOBEXenon Pharmaceuticals Announces Topline Results from Phase 2..
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:03GLOBEXenon Pharmaceuticals Provides Update on Partnered Program..
08/11/202322:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:11EDGAR2Form 8-K - Current report
08/11/202322:01GLOBEXenon Pharmaceuticals Reports Third Quarter 2023 Financial..
01/11/202321:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
09/10/202322:15GLOBEXenon Pharmaceuticals Announces Publication of Results from..
06/10/202314:30GLOBEXenon Pharmaceuticals to Present at Jefferies Inaugural..
14/9/202322:01GLOBEXenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual..
12/9/202322:30GLOBEXenon Pharmaceuticals Announces Upcoming Investor Webinar..
04/9/202314:30GLOBEXenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at..
31/8/202322:01GLOBEXenon Pharmaceuticals to Present at the Wells Fargo 2023..
11/8/202301:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202301:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/8/202300:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202300:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/8/202322:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:16EDGAR2Form 8-K - Current report
09/8/202322:01GLOBEXenon Pharmaceuticals Reports Second Quarter 2023 Financial..
08/8/202322:07EDGAR2Form 8-K - Current report
08/8/202322:01GLOBEXenon Pharmaceuticals Expands Leadership on its Board of..
02/8/202322:01GLOBEXenon Pharmaceuticals Announces Conference Call and Webcast..
06/6/202322:35GLOBEXenon Pharmaceuticals to Present at the Goldman Sachs 44th..
Apertura: 43,87 Min: 43,52 Max: 44,3672
Chiusura: 43,75

La tua Cronologia

NASDAQ
XENE
Xenon Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network